Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.

For 70 years MDA has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. As the largest source of funding for neuromuscular disease research outside of the US federal government, MDA has committed more than $1 billion since its inception to accelerate the discovery of therapies and cures.

The poster presentation includes the recently reported data from the Phase II clinical trial of the Company’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) where ATL1102 met the primary endpoint of the study with confirmation of the drug’s safety and tolerability. ATL1102 also demonstrated strong effects on secondary endpoints including activity on the targeted CD49d immune cells consistent with the drug’s proposed mechanism of action and outcomes on disease progression parameters that exceeded the Company’s expectations with improvement or stabilisation across different measures of muscle function and strength. The positive effects on disease progression were further supported by MRI data that suggested a stabilisation in the percentage of fat in muscles and preservation of functional muscle mass.

The Poster can be viewed on our website at the following link: Poster Presentation – Muscular Dystrophy Virtual Conference 2020

Mark Diamond, Chief Executive Officer of Antisense Therapeutics said: “Given the challenging times we are living in, MDA had to reimagine their annual conference and so have recently announced the launch of their 2020 MDA Virtual Conference Hub. Accordingly, we are very pleased that MDA have accepted our Phase II trial data for presentation. The Company is giving the clinical development of ATL1102 our highest priority. As we progress toward late stage clinical development, we intend to further increase international awareness of ATL1102’s therapeutic potential in boys suffering this terrible disease. The support of MDA and similarly oriented advocacy groups will greatly enhance attainment of that objective.”

About Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About MDA For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions. Our Resource Centre serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. Each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. During the COVID-19 pandemic, MDA continues to produce virtual events, programming, and advocacy to support our community when in-person events and activities are not possible. MDA’s COVID-19 guidelines and virtual events are posted at mda.org/COVID19. For more information, visit mda.org.

Antisense Therapeutics Mark Diamond Managing Director +61 (0)3 9827 8999 www.antisense.com.au

Investment Enquiries Gennadi Koutchin XEC Partners gkoutchin@xecpartners.com.au +61 423 500 233

US Enquiries Erin Cox erin.cox@antisense.com.au +1 206 579 3457

Antisense Therapeutics (ASX:ANP)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Antisense Therapeutics Charts.
Antisense Therapeutics (ASX:ANP)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Antisense Therapeutics Charts.